Kimberly Allison
Academic Appointments
- Associate Professor - Med Center Line, Pathology
Key Documents
Contact Information
-
Clinical Offices
Pathology Department 300 Pasteur Dr L235 MC 5324 Stanford, CA 94305 Tel Work (650) 724-3725Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Anatomic/Clinical Pathology
Administrative Appointments
- Associate Residency Director, Anatomic Pathology (2013 - present)
Professional Education
| Fellowship: | University of Washington Medical Center, WA USA (2005) |
| Board Certification: | Anatomic/Clinical Pathology, American Board of Pathology (2006) |
| Residency: | University of Washington Medical Center, WA USA (2006) |
| Medical Education: | New York Medical College NY (2001) |
| Board Certification: | Amercian Board of Pathology, Anatomic and Clinical Pathology (2006) |
| Fellowship: | University of Washington Medical Center, Surgical Pathology with focus of Breast/GYN Pathology (2005) |
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
Dr. Allisons clinical expertise is in breast pathology. Her research interests include how standards should be applied to breast cancer diagnostics (such as HER2 testing), the utility of molecular panel-based testing in breast cancer, and identifying the most appropriate management of specific pathologic diagnoses. She is also the author of Red Sunshine, a memoir about her personal experience with breast cancer, a topic which she speaks about to both patient and health care audiences.
Publications
- Development of a diagnostic test set to assess agreement in breast pathology: practical application of the Guidelines for Reporting Reliability and Agreement Studies (GRRAS). BMC Womens Health. 2013: 3
- A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression. Oncogene. 2012; (32): 3696-708
- Biomarkers of progestin therapy resistance and endometrial hyperplasia progression. Am J Obstet Gynecol. 2012; (1): 36.e1-8
- Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients. EJNMMI Res. 2012; (1): 34
- In vivo assessment of ductal carcinoma in situ grade: a model incorporating dynamic contrast-enhanced and diffusion-weighted breast MR imaging parameters. Radiology. 2012; (2): 374-82
- Lobular in-situ neoplasia on breast core needle biopsy: imaging indication and pathologic extent can identify which patients require excisional biopsy. Ann Surg Oncol. 2012; (3): 914-21
Help
